Logo image of 2HQ.DE

TILRAY BRANDS INC (2HQ.DE) Stock Fundamental Analysis

FRA:2HQ - Deutsche Boerse Ag - US88688T1007 - Common Stock - Currency: EUR

0.3705  -0.02 (-6.2%)

Fundamental Rating

2

Overall 2HQ gets a fundamental rating of 2 out of 10. We evaluated 2HQ against 53 industry peers in the Pharmaceuticals industry. The financial health of 2HQ is average, but there are quite some concerns on its profitability. While showing a medium growth rate, 2HQ is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year 2HQ has reported negative net income.
In the past year 2HQ has reported a negative cash flow from operations.
2HQ had negative earnings in each of the past 5 years.
2HQ had negative operating cash flow in 4 of the past 5 years.
2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCF2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

2HQ has a worse Return On Assets (-27.79%) than 79.25% of its industry peers.
2HQ has a Return On Equity of -34.64%. This is in the lower half of the industry: 2HQ underperforms 79.25% of its industry peers.
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
2HQ.DE Yearly ROA, ROE, ROIC2HQ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

2HQ has a Gross Margin of 30.88%. This is amonst the worse of the industry: 2HQ underperforms 81.13% of its industry peers.
2HQ's Gross Margin has declined in the last couple of years.
2HQ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
2HQ.DE Yearly Profit, Operating, Gross Margins2HQ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

2HQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 2HQ has been increased compared to 1 year ago.
2HQ has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 2HQ has been reduced compared to a year ago.
2HQ.DE Yearly Shares Outstanding2HQ.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
2HQ.DE Yearly Total Debt VS Total Assets2HQ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -0.80, we must say that 2HQ is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.80, 2HQ is not doing good in the industry: 77.36% of the companies in the same industry are doing better.
2HQ has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of 2HQ (0.11) is better than 79.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.8
ROIC/WACCN/A
WACC8.65%
2HQ.DE Yearly LT Debt VS Equity VS FCF2HQ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.62 indicates that 2HQ has no problem at all paying its short term obligations.
2HQ has a Current ratio of 2.62. This is amongst the best in the industry. 2HQ outperforms 88.68% of its industry peers.
2HQ has a Quick Ratio of 1.61. This is a normal value and indicates that 2HQ is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of 2HQ (1.61) is better than 84.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.61
2HQ.DE Yearly Current Assets VS Current Liabilites2HQ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

2HQ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.41%, which is quite impressive.
2HQ shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.23%.
Measured over the past years, 2HQ shows a very strong growth in Revenue. The Revenue has been growing by 78.86% on average per year.
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%

3.2 Future

Based on estimates for the next years, 2HQ will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.04% on average per year.
Based on estimates for the next years, 2HQ will show a small growth in Revenue. The Revenue will grow by 5.90% on average per year.
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y17.04%
Revenue Next Year8.45%
Revenue Next 2Y7.11%
Revenue Next 3Y5.97%
Revenue Next 5Y5.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
2HQ.DE Yearly Revenue VS Estimates2HQ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
2HQ.DE Yearly EPS VS Estimates2HQ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 2HQ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2HQ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2HQ.DE Price Earnings VS Forward Price Earnings2HQ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 2HQ indicates a slightly more expensive valuation: 2HQ is more expensive than 60.38% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.49
2HQ.DE Per share data2HQ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

A more expensive valuation may be justified as 2HQ's earnings are expected to grow with 21.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.62%
EPS Next 3Y21.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 2HQ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

FRA:2HQ (6/2/2025, 7:00:00 PM)

0.3705

-0.02 (-6.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-08 2025-04-08/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners11.8%
Inst Owner ChangeN/A
Ins Owners0.29%
Ins Owner ChangeN/A
Market Cap379.96M
Analysts72.22
Price Target1.13 (204.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.2%
Min EPS beat(2)-145.1%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-85.68%
EPS beat(12)1
Avg EPS beat(12)-398.32%
EPS beat(16)4
Avg EPS beat(16)-256.75%
Revenue beat(2)0
Avg Revenue beat(2)-8.97%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-7.31%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-2.67%
Revenue beat(12)1
Avg Revenue beat(12)-3.36%
Revenue beat(16)1
Avg Revenue beat(16)-7.96%
PT rev (1m)-4.99%
PT rev (3m)-39.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-150%
EPS NY rev (1m)-5.05%
EPS NY rev (3m)-439.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.94%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-5.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.52
P/FCF N/A
P/OCF N/A
P/B 0.16
P/tB 0.74
EV/EBITDA 18.49
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.71
BVpS2.33
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.88%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA 12.7
Cap/Depr 27.68%
Cap/Sales 4.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.61
Altman-Z -0.8
F-Score4
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y17.04%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%
Revenue Next Year8.45%
Revenue Next 2Y7.11%
Revenue Next 3Y5.97%
Revenue Next 5Y5.9%
EBIT growth 1Y-239.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.02%
EBIT Next 3Y37.28%
EBIT Next 5Y22.99%
FCF growth 1Y-24.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.12%
OCF growth 3YN/A
OCF growth 5YN/A